Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cancer cells to SN‑38, which inhibits topoisomerase I. This enzyme normally relaxes DNA during replication; its inhibition prevents DNA strand religation, causing DNA breaks that trigger cell death, especially in rapidly dividing tumour cells.

The dose of Irinotecan Accord is individualized by the treating physician based on factors such as tumour type, patient weight, performance status, and prior therapy. The prescribing oncologist determines the exact amount, schedule, and infusion rate for each patient.

Safety data for irinotecan in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be excluded, the drug is generally avoided in pregnant or nursing women unless the therapeutic benefit justifies the potential hazard.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Irinotecan and topotecan are the two main topoisomerase I inhibitors. Irinotecan is typically used for colorectal cancer and has a broader indication profile, while topotecan is mainly approved for ovarian and small‑cell lung cancers. Both share similar mechanisms but differ in pharmacokinetics, dosing schedules and toxicity patterns.

Irinotecan Accord should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken. Before use, reconstitute according to the manufacturer’s instructions and keep the prepared solution within the recommended time frame for infusion.

Irinotecan Accord is given by intravenous infusion, usually over 30‑90 minutes depending on the prescribed regimen. The infusion is performed in a clinical setting where vital signs can be monitored, and anti‑emetic pre‑medication is often provided to reduce nausea and vomiting.

The most serious adverse events include febrile neutropenia, severe diarrhoea that can progress to colitis or intestinal perforation, and hypersensitivity reactions such as anaphylaxis. Prompt recognition and supportive care are essential to manage these potentially life‑threatening complications.

Irinotecan Accord is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, in those with severe hepatic impairment, and in individuals receiving live vaccines during treatment. Caution is also advised for patients with pre‑existing bone‑marrow suppression or uncontrolled infections.